Australia markets open in 4 hours 42 minutes
  • ALL ORDS

    6,818.10
    +21.20 (+0.31%)
     
  • AUD/USD

    0.6792
    -0.0078 (-1.14%)
     
  • ASX 200

    6,629.30
    +16.70 (+0.25%)
     
  • OIL

    99.77
    -8.66 (-7.99%)
     
  • GOLD

    1,766.80
    -34.70 (-1.93%)
     
  • BTC-AUD

    29,726.89
    +317.87 (+1.08%)
     
  • CMC Crypto 200

    436.52
    -3.50 (-0.80%)
     

Orion Corporation: Managers’ transactions – Hilpi Rautelin

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Orion Oyj
Orion Oyj

ORION CORPORATION
MANAGERS’ TRANSACTIONS
6 MAY 2022 at 16.00 EEST

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Hilpi Rautelin
Position: Member of the Board/Deputy member

Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 14509/4/4
____________________________________________

Transaction date: 2022-05-05
Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details
(1): Volume: 593 Unit price: 0.00000 EUR
Aggregated transactions
(1): Volume: 593 Volume weighted average price: 0.00000 EUR

Orion Corporation

Timo Lappalainen

President and CEO

Olli Huotari

SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting